Food and Drug Administration

Joint meeting of the
Nonprescription Drugs Advisory Committee
and the
Pulmonary-Allergy Drugs Advisory Committee

January 24, 2006

The committee will discuss the continued need for thedesignation of OTC epinephrine-metered dose inhalers 
for the Treatment of asthma as an essential use of ozone-depleting substances (ODSs) under 
Sec. 2.125 (21 CFR 2.125).
 

Briefing Information

Wyeth Consumer Healthcare

Disclaimer

The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not
necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or
effectiveness of the product described in this document.

Essential Use Document

Briefing Document

FDA

Disclaimer

Portions of this document have been determined to be exempt from disclosure under the Freedom of Information Act
(the FOIA) (5 U.S.C. 552). These redacted portions will appear as white space on the screen or on the printed page.

FDA Backgrounder Table of Contents